---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-003539"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-02-09T23:59:59+00:00"
generated_at: "2026-06-27T09:49:07.442434+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Oncotelic launches new OT-101 corporate presentation; JV re-IPO funding on track

## Summary
- New corporate presentation deployed Feb 7, 2022, covering OT-101 therapeutic programs.
- OT-101 program on track to be fully funded by JV for re-IPO, per filing.
- No financial figures or milestones disclosed in the 8-K or attached exhibit.
- Presentation attached as Exhibit 99.1 but content not available for review.

## SEC filing metadata
- accession: 0001493152-22-003539
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-02-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/0001493152-22-003539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222003539/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-003539
- JSON: https://secwatch.observer/filing/0001493152-22-003539.json
- Plain text: https://secwatch.observer/filing/0001493152-22-003539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.